Parabilis Medicines Prices Upsized $670M IPO and Concurrent $75M Private Placement

summarizeSummary

Parabilis Medicines priced its upsized initial public offering at $20.00 per share, raising $670 million, alongside a $75 million private placement with Regeneron, securing nearly $700 million in net proceeds to fund its pipeline into 2029.

check_boxKey Events

• Upsized Initial Public Offering Priced

  Parabilis Medicines priced its upsized initial public offering of 33,500,000 shares of common stock at $20.00 per share, generating gross proceeds of $670 million.

• Concurrent Private Placement with Regeneron

  Regeneron Pharmaceuticals, Inc. agreed to purchase 4,166,666 shares of common stock in a concurrent private placement for $75.0 million at $18.00 per share (90% of the IPO price).

• Significant Capital Raise

  The combined offerings are expected to yield approximately $693.2 million in net proceeds, significantly extending the company's cash runway into the second half of 2029.

• Funding for Pipeline Advancement

  Proceeds will primarily fund the clinical development of zolucatetide in desmoid tumors (Phase 3) and other indications, and advance preclinical programs (ERG, AR ON, beta-catenin degraders) to Phase 1 clinical data.

auto_awesomeAnalysis

Parabilis Medicines, a clinical-stage biopharmaceutical company, has successfully completed its upsized initial public offering and a concurrent private placement, raising approximately $693.2 million in net proceeds. This substantial capital infusion is critical for a pre-revenue biotech, providing a cash runway into the second half of 2029. The funds are earmarked for advancing its lead product candidate, zolucatetide, into a registrational Phase 3 trial for desmoid tumors, expanding its clinical development into other indications, and progressing its preclinical pipeline. The participation of Regeneron Pharmaceuticals, Inc. in the private placement at a slight discount to the IPO price signals strong institutional confidence in Parabilis's Helicon discovery platform and product candidates. While the offering results in significant dilution for existing shareholders, the secured funding de-risks the company's operational runway and enables crucial R&D milestones.